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Abstract
Introduction. The value of PET-CT in radiotherapy for non-small cell lung cancer (NSCLC) with regard to determination of
target volumes is established. It is less clear whether its use can improve clinical outcomes of irradiated NSCLC patients
compared to conventional staging. The outcome of NSCLC patients included in a previously published prospective study of
the value of PET-CT in curative radiotherapy candidates was assessed.
Material and methods. Patients were treated according to the PET-CT findings. The survival data were compared between
67 patients treated curatively and 22 patients with palliative treatment given after upstaging based on the PET-CT findings.
Survival of curatively treated stage III patients was compared with a previously published outcome of 173 stage III patients
treated in the same institution with the same radiation schedule but without PET-CT.
Results. The 3-year overall survival was 42% and 0% (median: 21 months and 7 months), for curatively and palliatively
managed patients, respectively (p < 0.0001). However, the median overall survival of 17 months for 50 stage III patients
was the same as that in a previously published series of stage III patients treated with the same radiation schedule but
without PET-CT. Three-year overall survival rates were 33% for the PET-CT group and 19% for historical group, p = 0.1.
Twenty-one local recurrences and 21 distant metastases were reported. Three of 50 patients (6%) treated without elective
nodal irradiation developed isolated nodal failure (without local recurrence).
Conclusions. The high early mortality rate in the patients excluded from curative radiotherapy after PET-CT suggests the
potential value of PET-CT for improving the radiotherapy outcome. However, this benefit seems to be limited in stage III
patients.
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Introduction
The unquestioned role of positron emission
tomography combined with computed tomography
(PET-CT) in the diagnostics and treatment of non-
small cell lung cancer (NSCLC) is related to its
better accuracy in staging NSCLC in the mediasti-
num and in identification of distant metastases
when compared to conventional diagnostic moda-
lities, such as computed tomography (CT). The
results of PET-CT scanning lead to changes in the-
rapeutic strategies in many patients. The detection
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of distant metastases or locoregional disease upsta-
ging results in disqualification from radical radio-
therapy in 30% of patients [1]. Appropriate patient
selection with PET-CT scanning can decrease the
number of futile thoracotomies by 20% [2]. Many
patients not eligible for radical interventions can
avoid prolonged and toxic therapy owing to chan-
ges in treatment strategies after PET-CT. The inc-
lusion of PET-CT scans in radical radiotherapy
planning decreases the risk of geographical miss,
especially within the mediastinum [3–5], and in
some patients leads to a change of radiotherapy
technique, including the decision about the use of
elective nodal irradiation (ENI) [5].
Given the stage migration phenomenon [6] and
high early mortality rate in radically treated pa-
tients who underwent conventional diagnostic pro-
cedures [7], the potential benefits of PET-CT qu-
alification for radical therapy have been suggested,
with potentially prolonged survival [1, 7, 8]. A
trend towards improved overall survival in patients
with PET-CT-based diagnostics and radiotherapy
planning was observed in a Canadian prospective
randomized study on disqualifications from radio-
chemotherapy after PET-CT when compared to CT
alone in stage III NSCLC patients. Two-year ove-
rall survival rate of radically irradiated patients
was 53% in the PET-CT arm and 41% in the CT
arm (hazard ratio [HR] =0.7; 95% confidence in-
terval [CI]: 0.5–1.0; p = 0.045) [9]. There are, ho-
wever, no other randomized studies comparing the
results of radical radiotherapy planned with PET-
CT versus conventional CT-based radiotherapy.
Considering the established impact of PET-CT on
radiation target volumes design, such a randomi-
zed study could not be performed. The value of
PET-CT in radiotherapy may be similar to that in
surgically managed patients. In a Danish study, 200
patients with potentially resectable NSCLC were
randomised to conventional radiological imaging
(CT) and PET-CT scanning or CT alone. The per-
centage of futile thoracotomies was lower in the
first group, but this did not translate into signifi-
cant improvement in overall survival [10]. There-
fore, the role of PET-CT in NSCLC patients treated
with radiotherapy remains unknown. The thera-
peutic ratio of radiotherapy may be not that high
in NSCLC and radiotherapy given to patients with
metastases undetected by conventional diagnostic
modalities may also affect overall survival. Further
prospective studies on the survival of NSCLC pa-
tients treated with PET-CT are thus warranted.
The primary goal of a prospective study recen-
tly performed in our institution was to assess the
changes after PET-CT in radiotherapy plans in
NSCLC patients with a focus on the risk of geogra-
phical miss caused by a lack of PET-CT informa-
tion in patients with and without planned ENI [5].
Patterns of failure of radically irradiated patients
participating in that study was then prospectively
assessed. Herein we report the outcomes and pat-
terns of failure, including the incidence of isola-
ted nodal failures (INF), in NSCLC patients treated
within the framework of a prospective study, whe-
re, after PET-CT scanning, ENI was omitted only
for minimal N disease (N0, N1, single N2 of not
more than 3 cm in diameter). The survival data
were compared between patients treated curative-
ly and  patients with palliative treatment given
after upstaging based on the PET-CT findings. To
assess the impact of PET-CT on radiotherapy out-
comes, survival of curatively treated stage III
NSCLC patients was compared with a previously
published outcome of 173 stage III patients treated
in the same institution within the framework of a
prospective study with the same radiation schedu-
le but without PET-CT.
Material and methods
The details of the material and methods, and
the impact of PET-CT on therapeutic decisions and
radiotherapy plans in the study group have been
reported previously [5]. Briefly, 100 consecutive
stage I-III NSCLC patients referred for radical ra-
diotherapy underwent CT-based planning and then
PET-CT-based planning. The patients for whom the
decision about curative radiotherapy was mainta-
ined after PET-CT were treated according to the
PET-CT-based plan. Patients with stage III NSCLC
determined by conventional imaging had the ENI
included in the CT-only based plans. After PET-
CT, the stage III patients with minimal nodal di-
sease (N0, N1, and single N2) had ENI omitted from
the treatment plans. Before the onset of radiothe-
rapy, fit stage III patients were administered two
or three cycles of platinum-based chemotherapy.
The decision about curative radiotherapy was
maintained for 75 (75%) patients after PET-CT.
Twenty-four patients were referred for palliative
treatment: 19 because of distant metastases and five
because of too extensive locoregional disease. A
benign lesion was diagnosed in one patient.
According to the departmental protocols, the
patients were irradiated using three distinct sche-
dules as follows.
1. For early peripheral T1 to T3N0 tumors: 52 Gy
in 13 fractions, five fractions per week; radio-
therapy limited to the tumor with margins.
2. For early central T1 to T2N0–N1 and T3N0
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tumors: 66 Gy in 30 fractions over 6 weeks;
radiotherapy was limited to the tumor with
margins with inclusion of the ipsilateral hi-
lum, irrespective of hilar involvement.
3. For stage III tumors: 58.8 Gy over 4 weeks,
including 39.9 Gy for limited ENI in 21 frac-
tions, using a simultaneous boost technique
(2.8 Gy per fraction including 1.9 Gy for limi-
ted ENI). The limited ENI was used for N2–3
disease, except for single N2 < 3 cm in dia-
meter, and included only the lymph node sta-
tions with the highest probability for micro-
scopic invasion, i.e. the uninvolved ipsilate-
ral hilum, the 4R, 4L, 7, and for the left side,
the 5 lymph node station. Details of this tech-
nique were published previously [11]. Lymph
node stations were delineated according to the
published guidelines [12] with local modifi-
cation [13]. Stage III patients with N0, N1 or
single N2 < 3 cm in diameter confirmed after
PET-CT were treated with involved field ra-
diotherapy (IFRT), covering only the tumor
and pathological lymph node stations with
margins, and ENI was omitted.
Gross tumour volume (GTV) consisted of pre-
chemotherapy tumor volume, post-chemotherapy
volumes could be used in exceptional cases. No-
dal GTV was always based on pre-chemotherapy
nodal involvement. If the uptake of 18F-fluoro-
deoxy-glucose ([18F]-FDG) was greater than its
anatomic substrate on the fused image, the who-
le region of [18F]FDG enhancement was included
in the GTV. To avoid errors, if the [18F]FDG upta-
ke area was smaller than its anatomic substrate
on CT, the whole concerned structure was inclu-
ded in the GTV. [18F]FDG-PET-negative lymph
nodes measuring 1.5 cm or larger in short axis
diameter were considered pathologic and inclu-
ded in the GTV.
After completion of the PET-CT-based radical
radiotherapy, patients were followed up at 3-month
intervals. Follow-up assessment included medical
history, physical examination, chest X-ray, and
chest CT. Other examinations were performed for
symptomatic patients. PET-CT was not performed
in the follow-up period. Local progression was
defined as an increase in target disease of at least
20% in sum. Regional nodal recurrence in the ini-
tially uninvolved hilum, mediastinum, or supra-
clavicular areas without simultaneous or previo-
us local progression, was defined as INF regardless
of distant metastases. Histopathological verifica-
tion of any recurrence was not mandatory. Local
and distant recurrences were both recorded, irre-
spective of their time sequence.
Results of a prospective trial on the overall
survival of 173 stage III NSCLC patients treated
between 2001 and 2007 in the same institution
with the same radiotherapy schedule (and for fit
patients, sequential chemo-radiotherapy), but wi-
thout PET-CT staging, were previously published
[11]. Their survival was compared with that of the
stage III patients treated with PET-CT use inclu-
ded in the current study; log-rank test was used for
the comparison. Data concerning the outcomes of
NSCLC stage I or II patients irradiated in DTR wi-
thout PET-CT were not collected prospectively.
Therefore, comparisons of the outcomes of early
stage NSCLC patient treated with vs. without PET-
CT were abandoned.
Patients who received palliative treatment
after PET-CT were not systematically followed-up
in DTR, and only data on their survival were ava-
ilable. These were 24 patients referred for palliati-
ve treatment because of distant metastases or lo-
coregional disease too extensive for curative radio-
therapy.
Current analysis concerns the pattern of tre-
atment failure in the group that received radical
radiotherapy after PET-CT. The overall survival,
local progression-free survival, distant metastases-
free survival and the cumulative incidence of INF
were estimated using the Kaplan–Meier method.
Time intervals were calculated from the first day
of radiotherapy. The log-rank test was used to com-
pare the overall survival rates for patients who re-
ceived radical radiotherapy and those addressed
for palliative treatment. In patients who did not
receive radical radiotherapy, the survival rate was
calculated from the date of PET-CT scanning.
The Wilcoxon test for age and the nonparame-
tric Mann-Whitney U test for remaining parame-
ters (gender, performance status, weight loss, cli-
nical stage of disease, histological subtype, chemo-
therapy use) were used to determine the distribu-
tion of patient characteristics within each compa-
red group (palliatively treated vs radically treated
patients and the study stage III patients vs the hi-
storical group of stage III patients). A p-value of
less than 0.05 was considered statistically signi-
ficant.
Results
Among 75 patients with qualification for ra-
dical radiotherapy sustained after PET-CT, 67 were
treated and followed-up in DTR in Warsaw. These
patients were included in the analysis of the pat-
tern of failure. The characteristics of this subgro-
up are shown in Table 1. Seventeen (25%) radical-
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ly treated patients received ENI according to the
study protocol because of massive nodal involve-
ment (> 2 PET-positive lymph node stations or a
single lymph node station > 3 cm). In the rema-
ining 50 patients, IFRT was administered.
Median follow-up of  living patients who re-
ceived radical radiotherapy was 32 months (ran-
ge: 15–41 months). Local recurrences were obse-
rved in 21 patients, and distant metastases were
found in 21 patients. Brain was the most common
site of metastatic disease; isolated cerebral meta-
stases were identified in five of 67 patients (7.5%).
Isolated brain metastases were found in five of 52
(9.6%) patients with stage III disease. Estimated 3-
year overall survival was 42%, local progression-
free survival was 55%, and distant metastases-free
survival was 62%. Median overall survival was 21
months. Estimated three-year overall survival ra-
tes for stage III and stage I/II patients were 36% and
61%, respectively. Fifty-two stage III patients had
a median overall survival of 17 months, whereas
the median overall survival for stage I/II patients
has not been reached. For comparison of overall
survival of stage III patients with a historical co-
hort from the same institution, two patients treated
out of protocol were excluded; one of them rece-
ived 52 Gy in 13 fractions, and the other one 59.4
Gy in 33 fractions. Median and 3-year overall su-
rvival was 17 months and 33%, respectively. Me-
dian overall survival in 50 patients with stage III
disease was identical to that in the previously pu-
blished series of 173 patients treated in the same
institution and according to the same protocol but
without the inclusion of PET-CT in staging or ra-
diotherapy planning. The difference in overall su-
rvival between these two patient cohorts was not
statistically significant. Three-year overall survi-
val rate was 19% in the historical group and 33%
in the currently studied group (p = 0.10). Median
follow-up for living patients in the historical gro-
up was 32 months (range: 18–84 months). The cha-
racteristics of stage III patients from the current
study group and historical group are shown in
Table 1. There were no statistically significant dif-
ferences between both groups regarding median
age and the distribution of remaining analysed cli-
nical variables (sex, performance status, weight
loss, clinical stage, histological subtype, use of
chemotherapy).
Of the 24 patients referred for palliative treat-
ment after PET-CT, seven received chemotherapy,
12 were treated with palliative radiotherapy and
the remained five received supportive care only.
Two patients were lost to follow-up. Twenty- two
patients were included in the analysis of overall
survival. Their median overall survival was 7 mon-
ths (range: 2-26 months) and the estimated 2- and
3-year overall survival rates were 14% and 0%,
respectively. These values compare unfavorably
with those in curatively treated patients (p <
0.0001) (fig. 1). The characteristics of patients tre-
ated palliatively after PET-CT staging are shown
in Table 3. There were no statistically significant
differences between curatively and palliatively tre-
ated patients regarding median age and the distri-
bution of remaining analysed clinical variables
(sex, performance status, weight loss, clinical sta-
ge, histological subtype, use of chemotherapy).
Isolated nodal failures (INF) occurred in three
of 67 patients (4.5%).In all these cases ENI had
been omitted after PET-CT. In a group of 50 pa-
tients treated with IFRT the incidence of INF was
6%. Cumulative incidence of INF at three years was
10% (95% CI: 0–21%) for all irradiated patients and
12% (95% CI: 0–26%) for patients treated with
IFRT.
Discussion
We have shown a relatively good survival of
NSCLC patients managed with curative radiothe-
rapy, although the rate of INF seems higher as that
reported in other studies on PET-CT-based radio-
therapy. The difference in survival between pa-
tients irradiated radically and those referred for
palliation after PET-CT suggests that survival may
be improved in curatively treated patients staged
with PET-CT before radiotherapy. It may explain
an improvement in survival seen in the contem-
porary studies on curative radiotherapy [14]. Short
median overall survival in patients excluded from
curative radiotherapy reflects the high mortality
rate in this group of patients. If no PET-CT data
had been available, those patients would have been
treated with radical intention, which would com-
promise the overall outcome of radiotherapy.
The prospective randomised Positron Emis-
sion Tomography (PET) Imaging in Stage III Non-
small Cell Lung Cancer (PET-START) study [9]
included 310 patients with stage III NSCLC and
showed a trend towards improved survival after
PET-CT-based staging and radiotherapy planning,
when compared to conventional imaging tech-
niques. An Australian study [7] also showed an im-
provement in radiotherapy outcomes with the use
of PET-CT. The outcomes of stage I–III NSCLC pa-
tients included in the prospective study on radio-
and radiochemotherapy without PET-CT were
compared to the results of PET-CT-staged patients
included in another prospective study. A signifi-
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Table 1. The characteristics of 67 patients treated radically after PET-CT staging
Characteristics  Number (percent) of patients
Age Median 67 range 43–82
£ 70 40 (59)
> 70 27 (41)
Gender
Male 52 (78)
Female 15 (22)
Karnofsky performance status
90–100 46 (69)
80 21 (31)
Weight loss in the six months preceding radiotherapy
>10% 4 (6)
5–10% 8 (12)
No weight loss. or less than 5% 55 (82)
Histology
Squamous 29 (43)
Adenocarcinoma  6 (9)
Large cell 1(2)
Non small-cell lung cancer without further specification 29 (43)
No pathologic confirmation 2 (3)
*Clinical stage after PET
I 11 (16.5)
II 4 (6)
IIIA 21 (31)
IIIB 31 (46.5)
*T stage after PET
T1 11 (17)
T2 21 (31)
T3 7 (11)
T4 27 (40)
rT0† 1 (1)
*N stage after PET
N0 22 (33)
N1 10 (15)
N2‡ 30 (45)
N3 5 (7)
Neoadjuvant chemotherapy
Yes 34 (51)
No 33 (49)
Radiotherapy schedule
13 × 4 Gy 8 (12)
30 × 2.2 Gy 8 (12)
21 × 2.8 Gy; IFRT 34 (51)
21 × 2.8 Gy; z ENI 16 (24)
33 × 1.8 Gy^ 1 (1)
*TNM stage according to the TNM classification UICC 5th edition (1997)
†Includes one relapse after surgery (rT0N2)
‡Includes one relapse after surgery (rN2)
^Ower total dose and different fractionation schema for stage III patient resulted from location of the tumor close to the spinal cord; IFRT — involved-field radiotherapy
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Table 2. The characteristics of stage III patients from the PET-CT group# and historical group
Characteristics                                                                  Number (percent) of patients
Study group Historical group
Age Median 64, range 43-80 Median 63, range 44-82
£ 70 34 (68) 133 (77)
> 70 16 (32) 40 (23)
Gender
Male 38 (76) 133 (77)
Female 12 (24) 40 (23)
Karnofsky performance status
90–100 37 (74) 106 (61)
80 13 (26) 67 (39)
Weight loss in the six months preceding radiotherapy
> 5% 7 (14)  28 (16)
No weight loss, or less than 5% 43 (86)  145 (84)
Histology
Squamous 21 (42) 76 (44)
Adenocarcinoma 4 (8) 23 (13)
Large cell 1 (2) 2 (1)
Non small-cell lung cancer without further specification 22 (44) 72 (42)
No pathologic confirmation 1 (2) 0
*Clinical stage
IIIA 21 (42) 96 (55)
IIIB 29 (58) 77 (45)
Neoadjuvant chemotherapy
Yes 31 (62) 118 (68)
No 19 (38) 55 (32)
#50 patients included in the survival analysis
*TNM stage according to the TNM classification UICC 5th edition (1997)
cant reduction (45%) in NSCLC-related mortality
was observed in patients treated after PET-CT when
compared to the non-PET-CT group (p = 0.0075).
Nevertheless, multivariate analysis stratified by
whether chemotherapy was given and by the de-
gree of the weight loss (there was statistically si-
gnificant imbalance in the degree of weight loss
between the two groups), revealed the reduction
in an overall risk of death of 29% (HR = 71; 95%
CI: 0.45–1.1; p = 0.06). A German study [8] analy-
sed the impact of PET-CT on the outcomes of neo-
adjuvant radiochemotherapy (neoadjuvant radio-
chemotherapy, NARCT) in patients with stage III
NSCLC, treated within the framework of the same
prospective study.The first 115 patients underwent
PET-CT scan before qualification for NARCT; in
the remaining 78 patients only conventional ima-
ging without PET-CT was performed, due to finan-
cial constraints. Thirty-one patients in the PET-CT
group (27%) were excluded from curative treat-
ment due to the presence of distant metastases or
too extensive locoregional disease. Median overall
survival for patients treated curatively with vs.
without PET-CT was 22.3 vs. 11.3 months, respec-
tively. Univariate analysis showed a significantly
higher overall survival rate in the PET-CT group
(p = 0.006). The use of PET-CT was a single inde-
pendent prognostic factor influencing overall su-
rvival in multivariate analysis. Locoregional failure
rates were similar in both groups, whereas the PET-
CT group had a significantly lower incidence of
distant metastases – distant metastases-free survi-
val was significantly longer in that group. Thus,
better treatment outcomes after PET-CT resulted
from an appropriate patients’ selection, with the
exclusion of patients with N3 and/or M1 stage from
curative treatment.
Contrary to the above mentioned results, in the
current study median overall survival in stage III
patients (17 months) was identical as in the histori-
cal group of patients with same stage of disease, tre-
ated in the same institution according to the same
radiotherapy schedule (with or without chemothe-
rapy) but without PET-CT [11]. In this group of pa-
tients there was no correlation between PET-CT and
decrease in early mortality. Patients in the presen-
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ted study were not systematically evaluated for po-
tential brain lesions prior to therapy. Standard PET-
CT scan using fluorode-oxyglucose is unable to
identify potential brain lesions. The incidence of
isolated brain failures in a whole group of patients
with stage III disease was 9.6% (5 out of 52 patients),
so performing brain CT or MRI prior to radiothera-
py could contribute to further improvement of the
outcomes of curatively irradiated patients. The com-
parison with historical control and limited number
of patients in the presented study represent its ma-
jor limitations. That could contribute to the lack of
statistically significant differences in survival be-
tween curatively treated stage III patients, with vs.
without PET-CT. Patient qualification for curative
radiotherapy based on PET-CT results, however,
was associated with numerically improved three-
year overall survival rate (33% vs. 19% with and
without PET-CT, respectively). Therefore, PET-CT
permits the selection of patients who can benefit
most from curative treatment and achieve long-term
survival, as supported by the above-mentioned Ger-
man study results [8].
On the other hand, it is still possible that PET-
CT has limited value for stage III patients, since
more advanced locoregional disease carries a gre-
ater risk of micrometastases. This idea agrees with
a recent mediastinoscopy study revealing that >
30% of patients with stage III NSCLC have nodal
metastases undetected by PET-CT scan [15]. The
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Table 3. The characteristics of 22# patients treated palliati-
vely after PET-CT staging
Characteristics Number (percent) of patients
Age Median 64 range 50-82
£ 70 16 (73)
> 70 6 (27)
Gender
Male 16 (73)
Female 6 (27)
Karnofsky performance status
90–100 16 (73)
80 6 (27)
Weight loss in the six months preceding radiotherapy
>10% 1 (4.5)
5–10% 2 (9)
No weight loss. or less than 5% 19 (86.5)
Histology
Squamous 10 (46)
Adenocarcinoma 1 (4.5)
Large cell 1 (4.5)
Non small-cell lung cancer without further 8 (36)
specification
Carcinoid 1 (4.5)
No pathologic confirmation 1 (4.5)
#Among 24 patients qualified after PET-CT for palliative treatment two were
lost from the follow-up; 22 patients were included in the survival analysis
Figure 1. Overall survival for radically and palliatively treated patients
sensitivity of the PET-CT scan performed shortly
after completion of chemotherapy may be limited
[16], but prospective data suggest a strong correla-
tion of metabolic response to induction chemothe-
rapy and treatment outcomes and failures [17]. An
improvement in the outcomes of NSCLC patients
treated with radiotherapy with the use of PET-CT
is still to be demonstrated.
Three-year overall survival in stage I/II patients
was 61% in the presented study. A retrospective
analysis of treatment outcome in 132 patients with
early stages of disease, irradiated in our centre ac-
cording to various protocols before the PET-CT era,
revealed three-year overall survival rate of 37% [18].
The retrospective character of this study and lack
of a uniform treatment protocol limit our conclu-
sions, but comparison of these data and the results
of the presented study points to a possible survival
benefit of the use of PET-CT for qualification for
radiotherapy in early stage NSCLC patients as well.
An incidence of isolated nodal failures is hi-
gher in the presented study than in other series
where ENI was omitted after PET-CT [19, 20]. It is
an unexpected finding, especially when conside-
red that IFRT was administered only in patients
with low nodal stage (up to single N2 < 3 cm in
size). It cannot be excluded that longer follow-up
for living patients and prospective analysis of the
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site of failure in the presented study led to a hi-
gher incidence of INF as compared to other publi-
cations.
Conclusions
In conclusion, the outcome of NSCLC patients
managed with PET-CT-based irradiation shows a
relatively good efficacy of curative radiotherapy.
Despite a high rate of early mortality in patients exc-
luded from curative radiotherapy after PET-CT, me-
dian survival in stage III patients does not differ from
that of patients treated previously in the same insti-
tution with the same schedule but without PET-CT
use. This would suggest that the use of PET-CT in
diagnostics and treatment planning does not confer
a survival advantage in stage III patients. Obviously,
it does not compromise the utility of this imaging
method in these patients, especially when conside-
ring a previously demonstrated broad range of ad-
vantages related to its use. Numerically improved
three-year overall survival rate in patients irradiated
after PET-CT suggests the possibility of better iden-
tification of potential long-term survivors. The rate
of INF reported in this study seems meaningful and
cannot be neglected, since the therapeutic options
for NSCLC relapse are usually very limited.
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